Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.

Abstract

Glutamate regulates the function of central nervous system (CNS), in part, through the cAMP and/or IP3/DAG second messenger-associated metabotropic glutamate receptors (mGluRs). The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) has been extensively used to elucidate potential physiological and pathophysiological functions of mGluR5. Unfortunately, recent evidence indicates significant non-specific actions of MPEP, including inhibition of NMDA receptors. In contrast, in vivo and in vitro characterization of the newer mGluR5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) indicates that it is more highly selective for mGluR5 over mGluR1, has no effect on other mGluR subtypes, and has fewer off-target effects than MPEP. This article reviews literature on both of these mGluR5 antagonists, which suggests their possible utility in neurodegeneration, addiction, anxiety and pain management.

020040060020072008200920102011201220132014201520162017
Citations per Year

1,603 Citations

Semantic Scholar estimates that this publication has 1,603 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lea2006MetabotropicGR, title={Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.}, author={Paul M Lea and Alan I. Faden}, journal={CNS drug reviews}, year={2006}, volume={12 2}, pages={149-66} }